课题基金 / 基金详情

项目摘要

项目成果

SUBHASH C BASU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The immediate objectives of the proposed research are sixfold: 1. Separation, characterization, and purification of GalNAcT-2(UDP-GalNAc:GbOse3Cer(Betal-3)N-acetylgalactosaminyltransferase) and GalNAcT-3(UDP-GalNAc:GbOse4Cer(Alphal-3)N-acetyl-galactosaminyltransferase) present in the detergent solubilized supernatants from guinea pig tumor cell lines 104Cl (tumorigenic) and 106B(nontumorigenic), respectively. 2. Determination of the exact chemical linkages in the Forssman biosynthetic products of the 104Cl and 106B GalNAcT-3-catalyzed reactions. 3. Purification and kinetic studies of GalNAcT-1(UDP-GalNAc:GM3 or Lac-Cer(Betal-4)N-acetyl-galactosaminyltransferase) from guinea pig bone marrow. 4. Determination of the effects of tunicamycin and insulin on GalNAcT-2 and GalNAcT-3 activities in 104Cl and 106B guinea pig tumor cells. 5. Biosynthesis in vitro of the tumor-specific antigens sialosylAlpha2-3Le-x, sialosylAlpha2-3Le-a in neuroblastoma IMR-32 cells and GD3 and Fuc-GM1 in rat prostate PA-I/II cells. 6. Characterization of GalT-5(UDP-Gal:nLcOse4Cer(Alphal-3)galactosyltransferase) from neuroblastoma IMR-32 cells and study of its activity under various growth conditions during the cell cycle and in the presence of differentiating agent ((But)2cAMP and HMBA). Our overall goal is to develop an understanding of the specificities of glycolipid:glycosyltransferases in three tumor cell lines of guinea pig and human origin. Tunicamycin inhibits glycoconjugate biosynthesis. However, inhibition of glycosylation of glycosyltransferase is a novel observation. At the end of this project an attempt will be made to establish a correlation between inhibition of a glycosyltransferase (GalNAcT-2) by tunicamycin and the change of a tumor-specific antigen (Forssman GSL) on the surface of 104Cl and 106B cells using 125I-labeled Helix pomatia and Dolichos biflorus lectins and Siga toxin. Screening of the mouse genomic library, prepared from a partial EcoRI digestion of AJ mouse genomic DNA (Shotgun in Charon 4a) with a 32P-labeled cDNA insert of GalNAcT-2 will be performed. Using 125I-mono and polyclonal antibodies the translated products for particular 104Cl GalNAcT-2 DNA sequences will also be screened.
期刊论文(38)
专著(0)
科研奖励(0)
会议论文
Ceramide glycanase activities in human cancer cells.
人类癌细胞中的神经酰胺聚糖酶活性。
DOI: 10.1023/a:1020220524180
发表时间: 1999
期刊: Bioscience reports
影响因子: 4
作者: [Basu,M, Kelly,P, O'Donnell,P, Miguel,M, Bradley,M, Sonnino,S, Banerjee,S, Basu,S]
通讯作者: Basu,S
Biosynthesis in vitro of a blood group B-active fucose-containing hexaglycosylceramide from neolactopentaosylceramide in bovine spleen.
从牛脾中的新乳五糖基神经酰胺体外生物合成 B 型血活性岩藻糖的六糖基神经酰胺。
DOI: --
发表时间: 1982
期刊: The Journal of biological chemistry
影响因子: --
作者: [Presper,KA, Basu,M, Basu,S]
通讯作者: Basu,S
Inhibition of immunopurified DNA polymerase-alpha from PA-3 prostate tumor cells by platinum (II) antitumor drugs.
铂 (II) 抗肿瘤药物对 PA-3 前列腺肿瘤细胞中免疫纯化的 DNA 聚合酶-α 的抑制作用。
DOI: --
发表时间: 1993
期刊: Cancer biochemistry biophysics
影响因子: --
作者: [Kelley,TJ, Moghaddas,S, Bose,R, Basu,S]
通讯作者: Basu,S
DOI: 10.1007/s10719-006-7923-5
发表时间: 2006
期刊: Glycoconjugate journal
影响因子: 3
作者: [Boyle,PatrickJ, Ma,Rui, Tuteja,Narendra, Banerjee,Sipra, Basu,Subhash]
通讯作者: Basu,Subhash
32
    GLYCOLIPID METABOLISM IN NORMAL AND PATHOLOGICAL TISSUES
    • 批准号:
      2263328
    • 项目类别:
    • 资助金额:
      $18.48万
    • 财政年份:
      1981
    • 负责人:
      SUBHASH C BASU
    • 依托单位:
    GLYCOLIPID METABOLISM IN NORMAL AND PATHOLOGICAL TISSUES
    • 批准号:
      2447615
    • 项目类别:
    • 资助金额:
      $1.19万
    • 财政年份:
      1981
    • 负责人:
      SUBHASH C BASU
    • 依托单位:
    GLYCOLIPID METABOLISM IN NORMAL AND PATHOLOGICAL TISSUES
    • 批准号:
      2263329
    • 项目类别:
    • 资助金额:
      $15.94万
    • 财政年份:
      1981
    • 负责人:
      SUBHASH C BASU
    • 依托单位:
    GLYCOLIPID METABOLISM IN NORMAL AND PATHOLOGICAL TISSUES
    • 批准号:
      3398014
    • 项目类别:
    • 资助金额:
      $13.88万
    • 财政年份:
      1981
    • 负责人:
      SUBHASH C BASU
    • 依托单位:
    海外基金